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OBJECTIVES: Patient adherence with hypertension therapy is a leading cause for
uncontrolled blood pressure in the United States. The Anti-hypertensive Adher-
ence Survey (aHA Survey) was developed as a patient self-reported assessment of
therapy adherence. This study reports the psychometric properties and construct
validity of the tool. METHODS: The aHA Survey was administered to hypertensive
patients in a cross-sectional, non-interventional multisite study. The aHA Survey
comprises 25 items organized within six domains: Knowledge (9 items), Medical
Acceptance (3 items), Compliance (6 items), Finance (1 item), Willingness to
Change (4 items) and Depression (2 items). The aHA scoring algorithm assigns
points and designates intervention prompts based on patient’s responses to indi-
vidual items across each domain. Construct validity of the aHA Survey was evalu-
ated using an extension of the 1-parameter Rasch model for polytomous response
data when the items within a domain have unique rating domains and recall
periods, the Partial Credit Model. Unidimensionality was evaluated for the full
instrument and related scoring using goodness-of–fit statistics with an expected
range between 0.60-1.40. Reliability of the scores was assessed using the Rasch
person reliability estimate and the internal structure evaluated using Principal
Components Analysis. RESULTS: A total of 273 patients ere included in the study
(50.9% male, 89.7% Caucasian). Item fit was acceptable for all items on the aHA
Survey. The overall reliability for aHA Survey was moderate to high (alpha  0.84)
and 33.3% of the underlying variance in adherence was measured by the items on
the instrument. CONCLUSIONS: This study demonstrates the utility of measuring
a multi-dimensional phenomenon such as adherence in patient’s hypertensive
therapy using a brief 25-item assessment. The current items and related scoring
algorithm indicate good construct validity and reliability; which is imperative for
clinical utility. Validation against real-world data will be considered in the next
phase of research.
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OBJECTIVES: Gout is one of the most common inflammatory arthritides; it is com-
monly managed in primary care in the UK and has been associated with poor
cardiovascular (CV) outcomes. Allopurinol use has been associated with improved
outcomes, particularly at a higher dose (600mg/day); however, published studies
have shown that prescribed doses in the UK are 300mg or less. Adherence to allo-
purinol has not been well evaluated in the UK; we estimate the impact of adherence
to allopurinol on CV in gout patients in the UK. METHODS: The Health Improve-
ment Network (THIN) database from 1990 to 2009 was examined; patients aged 18
were identified using Read and drug codes. The CV-related outcomes were myo-
cardial infarction (MI), heart failure, stroke, peripheral thrombosis, angina and
coronary artery bypass. Adherence was measured using proportion of days covered
(PDC). Descriptive statistics were calculated and Kaplan-Meir survival curves were
constructed for different levels of adherence (PDC in quartiles). Analyses were
performed in a subset of patients that experienced a particular CV event during the
observation period. RESULTS:A total of 91,665 gout patients were identified, 39,747
of which were prescribed allopurinol; of these, 9% had MI, 18% had heart failure,
15% had stroke, 4% had thrombosis, 16% had angina and 5% had coronary artery
bypass. Mean PDC in patients prescribed with allopurinol was 0.72 (SD0.28).
Higher PDC was associated with increased survival time in all CV events except for
angina. PDC  0.75 resulted in substantially greater survival time. High adherence
has the greatest impact in MI and coronary artery bypass. CONCLUSIONS: Greater
adherence to allopurinol appears to be associated with better CV outcome in all
conditions except angina. A more profound effect in PDC higher than 0.75 suggests
that high adherence is needed to achieve clinical benefit.
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OBJECTIVES: To evaluate treatment persistence in patients receiving fixed-dose
combinations or unfixed combinations with olmesartan medoxomil (OLM) or val-
sartan (VAL) for hypertension treatment in Germany. METHODS: This retrospec-
tive study analyzed prescription data collected by general practitioners, using a
longitudinal database, the German IMS Disease Analyzer (DA). The DA database
was searched for patients with hypertension (ICD-10 code I10) who were initiated
on OLM or VAL in double combinations with hydrochlorothiazide (HCT) or amlo-
dipine (AML) in the period 09/2008 to 08/2009 with a follow-up of at least 12 months.
Persistence was defined as proportion of patients who remained on their initially
prescribed therapy at 1 year. RESULTS: In total, 2882 patients were eligible for
analysis (1079 patients receiving OLM, thereof 75.2% with fixed-dose combinations;
1803 patients receiving VAL, thereof 88.5% with fixed combinations). 12 months
after the first prescription, more patients receiving OLM stayed on their initial
therapy compared to VAL: unfixed combination with AML 27.4% vs. 25.2%; fixed-
dose combination with AML 47.3% vs. 44.6%; unfixed combination with HCT 25.0%
vs. 13.7%; fixed-dose combination with HCT 44.6% vs. 39.6%. Mean duration of
persistence in patients receiving OLM compared to VAL group was: 183.6 [SD 163.5]
days vs. 181.2 [SD 159.8] days in unfixed combinations with AML; 235.7 [SD 167.8]
days vs. 234.6 [SD 165.0] days in fixed-dose combinations with AML; 184.0 [SD 155.4]
days vs. 123.4 [SD 138.9] days in unfixed combinations with HCT; 228.5 [SD 167.8]
days vs. 222.9 [SD 165.6] days in fixed-dose combinations with HCT.
CONCLUSIONS:Overall, findings based on real-life prescription data suggest better
patient persistence with unfixed and fixed-dose OLM combinations compared to
respective VAL combinations. In terms of persistance not all angiotensin receptor
blockers perform equal rather hint at patient-individual treatment. Further re-
search is needed to confirm these first results.
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OBJECTIVES: Patient adherence with prevention and treatment of chronic disease
is challenging. Communication theory has potential to improve effectiveness of
interventions to improve adherence. This study used Theory of Reasoned Action
(TRA) variables to examine behavioral, normative injunctive and control beliefs
associated with statin adherence; association of beliefs with intentions and adher-
ence; and variation among subgroups (sex, race, treatment duration, primary vs.
secondary prevention). METHODS: Cardiology and primary care academic health
system patients prescribed statins January 2007 to December 2009 (n101,492).
Elicitation Study: Semi-structured telephone interviews (n40). Mail Survey: Ran-
dom sample stratified by race and prior CVD events (N1829). Causal path regres-
sion coefficients were compared using multi-group structural equation modeling,
stratified by race, gender and age. RESULTS: Elicitation Study: Respondents per-
ceived statin therapy as beneficial and reported supportive social norms and good
self-efficacy. Adherence failure was associated primarily with inability to act on
intentions rather than lack of intention. Mail Survey: Response50.2%; (53% male,
61% CVD event; 39% AA; mean age 65). AAs & women had lower intentions; AA
lower self-efficacy and normative pressure; older respondents higher self-efficacy;
secondary prevention higher normative pressure and behavioral beliefs. Males
were higher and those with perceived side effects lower for all three reasoned
action intention predictors. Non-event group: R2 intentions0.41. Adherence was
associated most strongly with attitudes. AAs were lower on all reasoned action
intention predictors. CVD event group: R2 Intentions0.20. Adherence was most
strongly associated with attitudes and self-efficacy. No socio-demographic variable
differentiated among intention predictors. CONCLUSIONS: Intentions and adher-
ence were associated most strongly with behavioral, normative and self-efficacy
beliefs and differed across demographic and prior event subgroups, suggesting
potential to improve adherence using targeted messages based on reasoned action
variables addressing subgroup specific beliefs. Intentions and adherence were pre-
dicted better for primary than secondary prevention, suggesting greater potential
for TRA-based targeted messages for those without a previous CVD event.
PCV106
PREDICTORS OF MEDICATION ADHERENCE IN A HYPERTENSIVE POPULATION
Saleemx F1, Hassali MA2, Shafie AA3, Bashir S4
1Universiti Sains Malaysia (USM), Pinang, Penang, Malaysia, 2Universiti Sains Malaysia,
Minden, Penang, Malaysia, 3Universiti Sains Malaysia (USM), Penang, Penang, Malaysia,
4University of Sargodha, Sargodha, Punjab, Pakistan
OBJECTIVES: The study aimed to assess predictors of medication adherence in a
hypertensive population of Pakistan. METHODS: This descriptive study was
shaped as a questionnaire-based cross sectional analysis. A prevalence based sam-
ple of 385 hypertensive patients was selected from 2 tertiary care hospitals. Hyper-
tension Fact Questionnaire (HFQ), Drug Attitude Inventory (DAI-10) and European
Quality of Life scale (EQ-5D) were used for data collection. Demographic and dis-
ease related information was also taken into account. SPSS versus 16.0 was used to
compute descriptive analysis of patients’ demographic and disease related infor-
mation. The factors that were significantly associated with adherence were further
assessed by binary logistic regression analysis. The analysis included only those
parameters with p value0.25 in Chi-square analysis. The power of independently
related parameters and predictive models were expressed as odds ratio (OR) with
95% confidence intervals (CI). The statistical significance was set at 0.05. RESULTS:
The mean age (SD) of the patients was 39.02 (6.596), with 68.8% males. The mean
SD duration of hypertension was 3.010.939 years. Forty percent (n154) had bach-
elor level of education with 34.8% (n134) were working in private sector. The
mean EQ-5D descriptive score was calculated 0.46740.28444 and EQ-Vas score
63.976.621. Mean knowledge and adherence scores were 8.03  0.42 and -1.74
2.154 respectively. The created model showed a significant goodness of fit as the
Omnibus Test of Model Coefficient was highly significant (Chi square 10.983, p
0.027, df  4). Knowledge score had significant association (adjusted OR 1.159,
95% CI 1.004 – 1.339, P 0.001) with medication adherence. CONCLUSIONS: From
the results of our study, it is concluded that improved knowledge towards hyper-
tension can result in better medication adherence. Patient education must be for-
malized and acknowledged as an official part of the health care system.
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OBJECTIVES: In this study, we seek to measure the association between physician-
rated adherence to antihypertensive treatment and blood pressure outcomes. Prior
to the study, we hypothesized that systolic and diastolic blood pressure outcomes
were also related with patient and physician variables. Therefore, we also seek to
determine the impact of these variables on the outcome. METHODS: Unlike prior
adherence studies, which have consulted small sample sizes by means of time-
consuming and complex questionnaires, our research pools the findings from six
Valsartan studies, thereby evaluating 15,583 patients, while utilizing a simple and
cost-effective survey method. Adherence was measured using a four-item yes/no
Basel Assessment for Adherence Scale (BAAS), in which a “yes” answer on any item
classified a patient as non-adherent. The measurements were performed at base-
line and at 90 days. Hierarchical logistic regression was used to identify patient-
and physician-related determinants. RESULTS: Our results indicate that inade-
quate blood pressure control correlates with poor adherence at baseline and 90
days. The mean absolute difference in blood pressure between those who were
adherent (70% of the patient population) and those who were not was 5 to 19 mmHg
(p0.001). Every adherent patient was likely to decrease his systolic and diastolic
blood pressure by 2.3 and 1.3 mmHg, respectively (p0.001). The majority of the
variability in blood pressure values, however, was due to patient variables, many of
which can be managed with medical care, or identified in patients with higher
risks, poor adherence, or poly-pharmacy. CONCLUSIONS: Physician-reported ad-
herence by means of a short patient BAAS questionnaire is a direct, simple and
especially inexpensive method to assess adherence status. This method can be
easily integrated into routine clinical practice and provides evidence that adher-
ence is positively correlated with blood pressure reduction in hypertensive pa-
tients. However, patient-related variables also correlate strongly with the outcome
and demand further investigation.
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OBJECTIVES: To derive Australian utility values for different health states associ-
ated with a new antiarrhythmic drug, dronedarone, for the treatment of patients
with atrial fibrillation (AF). METHODS: ŒOne hundred nineteen participants were
recruited by an independent research company. They ranged from 18–69 years
(mean age 44 years). Participants were presented information about AF, as well as
treatment for their disease. Participants were then presented with 8 health states
describing AF and its treatment and were asked to value these using a standard
gamble technique. RESULTS: The results demonstrated that participants had a
strong understanding of the condition and its treatment, and successfully valued
the health states, applying values derived for the 8 health states (AF, mild stroke,
moderate stroke, severe stroke, myocardial infarction, mild stroke and myocardial
infarction, moderate stroke and myocardial infarction, and severe stroke and myo-
cardial infarction) and their varying severity levels in a logical sequence. Values
ranged from 0.41 (SD  0.25) for the health state describing a patient with severe
stroke and myocardial infarction, to 0.78 (SD  0.22) describing a patient experi-
encing a mild stroke. CONCLUSIONS: Overall, the results of this study show that a
sample of the general Australian population is able to use the standard gamble
successfully to derive utility values for atrial fibrillation health states.
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Thailand Stroke is the common cause of death and disability worldwide. Survived stroke patients
have impairment and pass to long term disability. A little is known what the health utility of Thai
stroke patients is.
OBJECTIVES: To measure health utility of stroke patients and to compare those
using 4 measurement methods, i.e., visual analogue scale (VAS), standard gamble
(SG), time trade off (TTO) and European Quality of Life–5 Dimensions (EQ-5D).
METHODS: All 284 stroke patients at Ratchaburi Hospital were recruited between
August to October 2009 with the following criteria; aged over 20 years, contained
the Barthel ADL Index scores of over 25 and be able to communicate. The patients
were invited to participate in the study and respond to the questionnaire. Six parts
of the questionnaire included general information, the Barthel ADL index, VAS, SG,
TTO and Thai EQ-5D. Difficulty of each assessment method was ranked. Data were
then analyzed by ANOVA. RESULTS: The mean health utility of stroke patients
measured by VAS, SG, and EQ-5D were 0.70, 0.72, and 0.55, respectively. However,
the score evaluated by TTO could not be measured since the questionnaires were
too difficult for patients to understand. In addition, there was no significant differ-
ence between health utility measured by VAS and SG. However, a significant dif-
ference between VAS and EQ-5D, and between SG and EQ-5D were found.
CONCLUSIONS: Thai stroke patients’ health utility was moderate level. However,
there was a significant difference in utilities obtained from different methods.
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BACKGROUND: Venous thrombembolism (VTE) is a frequent event in the devel-
oped world and is associated with serious long-term complications, including post-
thrombotic syndrome, recurrent VTE, poor health-related quality of life (HRQL) and
death. VTE can manifest as deep venous leg thrombosis or lung embolism.
OBJECTIVES: To examine factors associated with HRQL in a randomized, double-
blind phase III trial comparing dabigatran etexilate to dose-adjusted warfarin in
acute VTE (RE-COVER). METHODS: Following parenteral treatment of acute VTE,
patients were randomized to oral dabigatran etexilate or warfarin for six months.
Patients completed the EQ-5D questionnaire at baseline, three and six months.
EQ-5D index scores (UK weights) were regressed on treatment, time since index
VTE, age, gender, race, ethnicity, smoking status, body weight, and various clinical
characteristics/conditions. Multivariate Censored Least Absolute Deviations
(CLAD), Tobit and Ordinary Least Squares (OLS) regression methods were com-
pared. EQ-5D questionnaire responses were also examined to identify the most
affected domains. RESULTS: There were 1245 patients on warfarin and 1264 on
dabigatran with valid EQ-5D scores at baseline; 1149 and 1150, respectively, at trial
end. After controlling for covariates, the following factors were statistically signif-
icant (p0.05; CLAD) and exhibited the largest magnitude changes in EQ-5D index
scores (from largest to smallest): 6 months post VTE (0.21), 3 months post VTE
(0.192), recurrent DVT (-0.17), underweight (-0.09), female (-0.08), morbidly obese
(-0.07), recurrent pulmonary embolism (-0.06), heart failure (-0.05), age 65 (-0.04)
and clinically relevant bleeding (-0.03). There were no statistically significant dif-
ferences between treatment groups. All regression methods yielded comparable
results. Domains most affected by VTE were mobility, usual activities and
pain/discomfort. CONCLUSIONS: Results of the RE-COVER trial demonstrate that
HRQL after VTE is largely dependent on the time from event rather than choice of
treatment. Further, significant differences in HRQL were associated with certain
clinical and patient characteristics.
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OBJECTIVES: Assess the burden of peripheral arterial disease (PAD) on patient
health-related quality of life (HRQoL), work productivity, health care resource use,
and to estimate the related direct and indirect costs in patients with PAD in five EU
countries. METHODS: Cross-sectional data were obtained from the 2010 EU Na-
tional Health and Wellness Survey, an internet-based survey in adults. Patients
with PAD were identified based on a self-reported PAD diagnosis. We assessed
HRQoL (SF-12v2 and estimated health utility), healthcare resource use in previous
6 months and work productivity in previous 7 days (Work Productivity and Activity
Impairment questionnaire) reported by respondents with and without self-re-
ported PAD diagnosis. Resource use and work productivity loss were monetized on
an annual basis to provide per-person cost estimates (2010 Euros). RESULTS: We
identified 743 respondents with (France 278, Germany 151, UK 69, Italy 159, Spain
86) and 57,062 without PAD. Compared to non-PAD respondents, those self-report-
ing PAD were older (mean age 58.1 vs. 46.3 years), had more comorbidities, reported
lower mean (SD) HRQoL scores [mental summary: 43.4 (11.4) versus 46.6 (10.6);
physical summary: 37.6 (11.2) versus 48.8 (9.7); health utilities: 0.63 (0.12) versus
0.73 (0.13)], greater mean (SD) percentage of absenteeism [12.1 (27.7) versus 5.4
(19.2)], higher mean (SD) health care utilization over 6 months [physician office
visits 11.9 (13.7) versus 5.3 (7.4), emergency room visits 0.40 (1.6) versus 0.19 (1.1),
hospitalizations 0.39 (1.5) versus 0.13 (1.2)], and higher total median (SD) direct
[1,329 (3,198) versus 544 (2,630) €] and indirect [8,850 (10,244) versus 4,015 (7,135) €]
yearly costs. CONCLUSIONS: Respondents with self-reported PAD reported lower
HRQoL scores and generated greater direct and indirect costs suggesting that PAD
poses a significant health burden to patients and society in Europe. Better manage-
ment of PAD may improve patient quality of life and reduce societal costs associ-
ated with the disease.
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OBJECTIVES: To evaluate and compare patient satisfaction in stroke prevention in
atrial fibrillation (SPAF) in Europe. Interim results are presented to initiate discus-
sions and guide analysis for the main survey. METHODS: A survey based on the
Commonwealth Fund Survey (2008) for chronically ill adults is applied to patients
with SPAF, with few disease-specific adjustments made. The survey is carried out
with structured randomized anonymous telephone interviews in France, Ger-
many, Italy, Spain and UK, screening for respondents with AF aged over 18. Total
pilot sample size is 152 respondents, evenly divided per country. RESULTS: The
pilot results indicate differences to other chronically ill patients and country vari-
ations. Mean age of respondents is 67, 50% female. Overall, 43% of the respondents
are totally satisfied with their health care system (highest in the UK: 57%). Most
frequent co-morbidities are hypertension (66%) and heart disease, including heart
attack (53%) beside arthritis, depression, chronic lung problems, diabetes, cancer –
with an average of 2,2 co-morbidities per respondent, regularly on 5,4 different
prescriptions. Ten percent had a period when they were uninsured (highest with
20% in the UK) and 11% had problems with unpaid medication (highest in Germany
with 33%) or refusal of payment by the insurance 9% (highest in France with 27%).
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